| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.069 | 0.02 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.02 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.02 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.02 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.02 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.02 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.081 | 0.02 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.02 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.02 |